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Abstract
In	this	brief	review	paper,	we	will	summarize	the	State-	of-	the-	Art	on	how	platelet	re-
activity	is	regulated	in	circulation	and	at	sites	of	vascular	injury.	Our	review	discusses	
recent	and	ongoing	work	presented	at	this	year’s	International	Society	on	Thrombosis	
and	Haemostasis	(ISTH)	meeting,	on	the	role	of	platelets	in	(i)	classical	hemostasis	at	
sites	 of	mechanical	 injury,	 and	 (ii)	 the	maintenance	 of	 vascular	 integrity	 at	 sites	 of	
inflammation.
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1  | CLASSICAL HEMOSTASIS—
BALANCING PLATELET ADHESIVENESS 
IN CIRCULATION AND AT THE 
VASCULAR INTERFACE
Platelets	are	critical	for	the	body’s	response	to	vascular	injury.	To	form	
a	hemostatic	plug,	they	rely	on	a	signal	transduction	machinery,	which	
is	optimized	to	sense	and	respond	to	minor	changes	 in	the	environ-
ment,	and	to	mediate	a	near-	immediate	conversion	of	cell-	surface	in-
tegrins	from	an	anti-	adhesive	to	a	pro-	adhesive	state.	While	patrolling	
the	vasculature,	however,	platelet	 activation	has	 to	be	prevented	 in	
order	to	avoid	thrombocytopenia	and/or	thrombosis.	In	this	first	sec-
tion	of	our	review,	we	will	discuss	the	exquisite	balance	between	acti-
vating	and	inhibitory	mechanisms	that	control	platelet	adhesiveness	in	
the circulation and at sites of vascular injury.
To	efficiently	plug	a	vascular	lesion	and	prevent	blood	loss	into	
the	surrounding	tissue,	platelets	have	evolved	highly	specialized	ad-
hesion	mechanisms,	which	enable	cell-	matrix	and	cell-	cell	 interac-
tions	in	the	presence	of	fluid	shear	stress.	Initial	platelet	recruitment	
at	sites	of	vascular	 injury	 is	mediated	by	glycoprotein	 (GP)	 Ib-	V-	IX	
Essentials
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complex	binding	to	von	Willebrand	factor	(VWF).	This	interaction	has	
a sufficiently fast association rate to enable platelet capture even at 
very	high	shear	rates,	but	it	supports	only	transient	adhesion.	Thus,	
it	serves	the	purpose	of	decelerating	platelets	in	the	proximity	of	the	
lesion,	and	allow	enough	time	for	the	platelets	to	become	activated	
and	engage	more	stable	adhesive	interactions.1	Firm	adhesion	is	me-
diated	by	receptors	that	belong	to	the	integrin	superfamily.	Integrins	
are transmembrane αβ	heterodimers	that	are	expressed	on	the	sur-
face	of	resting	platelets	 in	a	 low-	affinity	binding	state.	Stimulation	
of	 platelets,	 via	 extracellular	 matrix	 (ECM)	 molecules	 exposed	 at	
the	site	of	injury	(eg,	collagen),	and/or	locally	generated	soluble	ag-
onists	 (eg,	 thrombin),	 triggers	 intracellular	 signaling	 cascades	 that	
ultimately	 lead	 to	 the	 inside-	out	activation	of	 integrins.	 Important	
in	 this	process	 is	 the	 recruitment	of	 the	FERM-	domain	containing	
proteins,	TALIN2,3	and	KINDLIN3,4	to	the	integrin	cytoplasmic	tail.5 
Once	bound,	TALIN	triggers	conformational	changes	 that	 increase	
integrin	ligand-	binding	affinity,6	while	KINDLIN3	promotes	multiva-
lent	ligand	binding	by	increasing	the	local	density	(avidity)	of	TALIN-	
activated	 integrins.7	TALIN	 and	KINDLIN3	 are	 also	 directly	 linked	
to	the	cytoskeleton	and	increasing	evidence	presented	at	the	2017	
ISTH	 conference	 suggests	 that	 altered	 cytoskeletal	 dynamics	may	
result	 in	 dysregulated	 integrin	 activation.8–10	 Active	 β1	 integrins	
(α2β1,	α6β1,	α5β1)	support	adhesion	to	the	ECM	for	the	first	plate-
let	 layer,	which	 then	 becomes	 a	 new	 reactive	 surface	 for	 further	
platelet	 deposition.	 Active	 αIIbβ3	 integrins,	 which	 are	 extremely	
abundant	on	the	platelet	surface,	bind	multivalent	plasma	proteins	
(eg,	fibrinogen	or	VWF)	that	bridge	adjacent	activated	platelets	and	
thus	support	platelet-	platelet	cohesion.11,12
The	main	signals	 that	drive	the	three-	dimensional	growth	of	 the	
hemostatic	plug	are	 soluble	agonists	 (Figure	1),	 such	as	 the	product	
of	the	coagulation	cascade,	thrombin,	or	the	second	wave	mediators	
released	 from	activated	platelets,	adenosine	diphosphate	 (ADP)	and	
thromboxane	 (Tx)A2.	 Being	 soluble,	 these	 agonists	 can	 recruit	 free-	
flowing	platelets	into	the	growing	thrombus.	Soluble	agonists	bind	to	
G	protein	coupled	receptors	(GPCRs),	which	induce	a	very	rapid	and	
robust	signaling	response.13–15	The	key	to	GPCR	signaling	is	the	acti-
vation	(GTP	loading)	of	heterotrimeric	G	proteins.	The	GPCR	hereby	
serves	as	a	guanine	nucleotide	exchange	factor	(GEF),	which	induces	
the release of GDP from the alpha subunit of the heterotrimeric G 
protein.	Since	GTP	loading	of	the	nucleotide-	free	G	protein	happens	
very	rapidly,	this	on-	switch	mechanism	provides	a	perfect	system	to	
transduce	signals	on	a	millisecond	scale	required	for	platelet	adhesion	
under	high	shear	stress	conditions.
To	 keep	 these	 highly	 sensitive	 receptors	 in	 check,	 activation	 by	
soluble	agonists	 is	not	an	all-	or-	nothing	process.	 In	 fact,	 it	 is	a	 two-	
step	 process,	 carried	 out	 by	 dual	 receptor	 systems.	Thrombin	 stim-
ulates	 human	 platelets	 through	 the	 protease-	activated	 receptors,	
PAR1	and	PAR4,	while	ADP	activation	occurs	through	the	purinergic	
receptors,	P2Y1	and	P2Y12.	PAR1	 is	 triggered	by	very	 low	concen-
trations	of	 thrombin,	but	 it	also	rapidly	desensitizes.	Thus,	 it	 is	criti-
cal	 for	high	sensitivity	to	thrombin	and	a	fast	but	reversible	 integrin	
activation	 response.	PAR4	binds	 thrombin	with	much	 lower	affinity,	
F IGURE  1 Platelets	at	the	vascular	interface.	(A)	Mechanical	injury.	Shown	is	a	hemostatic	plug	with	platelets	activated	via	the	ITAM	
signaling	pathway	(blue	color)	or	the	GPCR	signaling	pathway	(red	colors).	Lighter	shades	of	red	indicate	weaker	cellular	activation.	ITAM	
signaling	plays	a	minor	role	in	hemostatic	plug	formation,	as	only	few	platelets	(blue)	are	in	direct	contact	with	the	extracellular	matrix	(ECM).	In	
contrast,	GPCRs	like	PAR1/4	and	P2Y12,	receptors	that	sense	soluble	agonists,	play	a	critical	role.	The	GPIb-	V-	IX	complex	and	integrin	αIIbβ3 
are	critical	for	transient	and	firm	platelet	adhesion,	respectively.	The	CalDAG-	GEFI/RAP1A-	B	signaling	pathway	is	critical	for	rapid	integrin	
activation	following	GPCR	engagement.	(B)	Inflammation.	Shown	are	small	gaps	between	endothelial	cells,	induced	by	infiltrating	leukocytes	
(not	shown),	and	single	platelets	that	occupy	these	gaps.	Due	to	their	direct	contact	with	the	ECM,	platelet	adhesion	at	sites	of	inflammation	is	
strongly	dependent	on	the	ITAM	receptors,	GPVI	and	CLEC2,	and	downstream	signaling	molecules,	such	as	SLP-	76	and	PLCγ2
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but	 it	also	internalizes	more	slowly	and	thus	generates	a	steady	and	
sustained	 integrin	 activation	 signal.16–18	 Similarly,	 the	ADP	 receptor	
P2Y1,	which	is	not	very	abundant	on	the	platelet	surface,19 is rapidly 
desensitized.20,21	Thus,	it	can	only	cause	a	rapid	but	short-	lived	rise	of	
the	 cytosolic	 calcium	 concentration	 and	 needs	 co-	signaling	 through	
the	P2Y12	receptor	to	support	platelet	aggregation.22,23	So	both	PAR1	
and	P2Y1	are	very	sensitive	and	provide	a	fast	but	reversible	activation	
response,	while	PAR4	and	P2Y12	are	required	to	sustain	the	signal.	As	
only	the	stimulation	of	both	receptors	provides	an	integrated	response	
that	is	both	rapid	and	sustained,	this	provides	an	elegant	mechanism	
to	limit	thrombus	growth	in	the	outer	layers	of	the	thrombus,	where	
agonist	concentrations	diminish.
Duration	and	intensity	of	the	GPCR	signal	are	limited	not	only	by	
receptor	desensitization	but	also	by	Regulator	of	G-	protein	Signaling	
(RGS)	proteins	that	increase	the	rate	of	GTP	hydrolysis	and	return	G	
proteins	 to	 the	 inactive	state.	Consistently,	 it	was	previously	 shown	
that	knockdown	of	RGS18,24,25	RGS10,26 or mutation of the RGS bind-
ing	site	on	Gαi27	 results	 in	 increased	platelet	reactivity.	At	this	 ISTH	
conference,	Gupta	et	al.	confirmed	that	knockdown	of	RGS10	results	
in	a	gain	of	platelet	function,	 in	particular	in	response	to	stimulation	
by	 the	 second	wave	mediators,	ADP	and	TxA2.
28	Unexpectedly,	 the	
same	group	reported	preliminary	studies	that	defective	RGS	binding	
to Gαq	causes	a	decrease	in	platelet	activation.29 The reasons for this 
surprising	platelet	hypofunction	are	currently	unclear.
In	addition	to	GPCRs,	platelets	sense	the	environment	through	the	
ITAM-	coupled	receptors	GPVI	and	CLEC-	2,	which	predominantly	inter-
act	with	the	ECM	protein	collagen	and	the	extravascular	protein	podo-
planin,	respectively.	The	ITAM	signaling	cascade	evolved	from	immune	
cells	that	signal	over	much	longer	time	scales	than	platelets	(minutes	vs	
seconds).	And	even	though	GPVI	has	adapted	to	meet	the	accelerated	
temporal	 needs	 of	 hemostasis,30	 the	 ITAM	 signaling	 response	 is	 still	
slower	compared	to	the	GPCR	response.	Consistently,	the	mild	bleed-
ing	phenotype	of	patients31,32 or mice33,34	lacking	GPVI	suggests	that	
this receptor has a minor role in classical hemostasis when compared to 
the major GPCRs.15	Surprisingly,	GPVI	was	shown	to	be	more	import-
ant	for	thrombus	stabilization	than	for	thrombus	initiation,35	suggesting	
the	existence	of	ligands	other	than	collagen.	Fibrin,	a	protein	deposited	
throughout	the	hemostatic	plug,	could	be	this	ligand.36,37	At	this	ISTH	
meeting,	Haining	et	al.	 reported	 that	CLEC-	2	 also	 appears	 to	have	a	
function	in	thrombus	stabilization,	independent	of	its	signaling	function	
and	 thus	potentially	by	binding	an	unknown	 intravascular	 ligand.38,39 
While	it	is	not	the	major	player	in	classical	hemostasis,	ITAM	signaling	
is critical for another form of hemostasis that is responsible for main-
taining	vascular	integrity	at	sites	of	inflammation40	(see	next	section).
Most	GPCRs	 and	 ITAM-	coupled	 receptors	 induce	 the	 activation	
of	phospholipase	C	(PLC),	a	key	enzyme	in	the	generation	of	the	sec-
ond	messengers,	calcium	and	diacylglycerol.	At	this	ISTH	meeting,	we	
presented	definitive	evidence	that	the	small	GTPase	RAP1	is	the	main	
signaling	 node	 that	 integrates	 these	 second	messenger	 signals	with	
integrin	activation.41 Previous studies in other cells42–45 and in heter-
ologous	 cell	 lines	expressing	αIIbβ346	 suggested	 that	RAP1	controls	
integrin	conversion	to	a	high	affinity	state	by	recruiting	TALIN	to	the	
plasma	membrane.	However,	platelets	lacking	the	most	abundant	RAP	
isoform,	RAP1B,	only	displayed	a	partial	 integrin	activation	defect.47 
Since	systemic	deficiency	of	the	closely	related	isoform,	RAP1A	was	
reported	to	have	no	effect	on	platelet	aggregation	(unpublished	obser-
vation47),	this	led	to	the	wrong	belief	that	there	is	a	powerful	RAP1-	
independent	signaling	pathway	that	can	mediate	integrin	activation	in	
platelets.48	Employing	mice	where	Rap1a and/or Rap1b were condi-
tionally	deleted	in	the	megakaryocyte/platelet	 lineage,	we	have	pro-
duced	preliminary	data	(presented	at	the	ISTH	meeting)	supporting	a	
role	for	both	RAP1A	and	RAP1B	in	platelet	integrin	activation.41 When 
comparing	the	Rap1a/b-	double	deficient	mice	to	Talin1-	deficient	mice,	
we	 found	 that	 there	 is	very	 limited	 integrin	 activation,	mediated	by	
TALIN1,	in	platelets	lacking	both	RAP1	isoforms.	Importantly,	this	re-
sidual	RAP1-	indendent	integrin	activation	can	only	support	slow	and	
sub-	maximal	aggregation	in	vitro,	while	it	was	not	sufficient	to	support	
hemostatic	plug	formation	in	vivo.41	Thus,	the	RAP1/TALIN	signaling	
axis	is	critical	in	platelet	integrin	activation	and	classical	hemostasis.
There	 is	 a	very	 rational	 explanation	 for	why	RAP1A	and	RAP1B	
are	critical	 in	hemostatic	plug	formation.	RAP	GTPases,	 like	the	het-
erotrimeric	G	proteins,	are	molecular	switches	that	can	be	turned	on	
rapidly	by	GEF-	mediated	GTP	for	GDP	exchange.	The	main	RAP-	GEF	
in	 platelets	 is	 CalDAG-	GEFI,	 a	 multidomain	 protein	 predominantly	
found in blood cells.49,50 Studies in mice51,52 and humans53–55	lacking	
functional	CalDAG-	GEFI	strongly	suggest	that	its	nucleotide	exchange	
activity	towards	RAP1	is	directly	controlled	by	the	binding	of	calcium	
to	a	pair	of	EF	hands	in	the	regulatory	domain.	Thus,	CalDAG-	GEFI	can	
sense	agonist-	induced	changes	in	the	cytosolic	calcium	levels.56 The 
result	is	a	near-	immediate	integration	of	second	messenger	generation	
and	integrin	activation.	Lack	of	CalDAG-	GEFI	leads	to	impaired	throm-
bus	formation	and	bleeding.51,53–55,57–60
CalDAG-	GEFI-	mediated	 RAP1	 activation	 is	 antagonized	 by	 the	
GTPase	activating	protein	 (GAP),	RASA3.61	Like	RGS	proteins,	GAPs	
are important to enhance GTP hydrolysis and to return small GTPases 
back	 to	 the	 inactive	 state.	 RASA3	 is	 active	 in	 circulating	 platelets,	
where	it	 is	required	to	counteract	any	unwanted	RAP	activation	and	
to	 keep	 the	 cells	 in	 a	 quiescent	 state.	Mice	 lacking	Rasa3 are char-
acterized	by	platelet	preactivation	and	severe	thrombocytopenia	due	
to	 increased	 platelet	 clearance.	At	 sites	 of	vascular	 injury,	 however,	
this	 negative	 feedback	 is	 detrimental	 to	 hemostatic	 plug	 formation.	
For	firm	platelet	adhesion	to	occur,	RASA3	activity	has	to	be	down-	
modulated.	Critical	for	the	down-	modulation	of	Rasa3	activity	is	sig-
naling	via	the	Gi-	coupled	receptor	for	ADP,	P2Y12.61	Thus,	similar	to	
the	GPCR	dual	receptor	systems,	RAP	activation	is	a	two-	step	process.	
A	rapid	but	reversible	activation	step,	mediated	by	calcium/CalDAG-	
GEFI	signaling,	is	followed	by	a	second	step,	RASA3	inactivation,	that	
is	 required	 to	 sustain	 the	 signal.	Again,	 this	 two-	step	 system	 is	 im-
portant	to	facilitate	controlled	platelet	adhesion	and	thrombus	growth	
under	high	shear	stress	conditions.
What	 is	 special	 about	 the	 RAP1	 signaling	 pathway,	 however,	 is	
how	tightly	controlled	it	has	to	be	in	order	to	avoid	serious	complica-
tions	for	the	organism.	The	affinity	for	calcium	of	the	CalDAG-	GEFI	EF	
hands	is	~80	nmol	L−1,56	a	value	that	is	only	minimally	higher	than	the	
cytosolic	 calcium	 concentration	measured	 in	 resting	 platelets	 (~20-	
50	nmol	L−1).	Given	these	numbers,	 it	can	be	concluded	that	 (i)	only	
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minimal	changes	in	cytosolic	calcium	are	required	to	mount	a	robust	
CalDAG-	GEFI	response,	and	(ii)	 that	some	CalDAG-	GEFI	protein	ex-
ists	in	an	active	conformation	even	in	circulating,	quiescent	platelets.	
Consistent	with	these	conclusions,	complete	CalDAG-	GEFI	deficiency	
is	ill	tolerated	as	it	causes	moderate	to	severe	bleeding	in	humans	and	
mice.51,53–55,58–60	 At	 the	 same	 time,	 CalDAG-	GEFI/RAP1	 signaling	
has	to	be	restrained	by	RASA3	in	circulating	platelets	to	avoid	severe	
thrombocytopenia	and	blood-	lymphatic	mixing	in	the	developing	em-
bryo.	Together,	these	specialized	mechanisms	ensure	the	tight	regula-
tion	of	platelet	adhesiveness,	which	is	crucial	for	the	platelets’	ability	
to	efficiently	form	a	stable	and	self-	limiting	hemostatic	plug	at	sites	of	
vascular	injury.	However,	platelets	are	also	important	for	the	mainte-
nance	of	vascular	integrity	at	sites	of	inflammation,62 where a different 
platelet	response	is	required	to	seal	small	gaps	in	the	endothelial	lining.
2  | VASCULAR INTEGRITY VS 
HEMOSTATIC PLUG FORMATION—
LESIONS OF DIFFERENT SIZE REQUIRE 
UNIQUE PLATELET RESPONSES
As	 outlined	 above,	 platelet	 function	 during	 hemostatic	 plug	 forma-
tion	depends	 strongly	 on	G	protein	 signaling.	Hemostatic	 plugs	 are	
aggregates	 of	 platelets,	 where	 only	 few	 of	 these	 cells	 make	 direct	
contact	 with	 the	 ECM	 in	 the	 damaged	 vascular	 wall	 (Figure	1A).	
GPCRs	 sense	 soluble	agonists	 that	diffuse	 into	 the	 lesion,	 and	 they	
initiate	a	platelet	signaling	response	characterized	by	the	very	rapid	
activation	of	PLC	and	the	generation	of	second	messengers.	The	on-	
off	nature	of	the	small	GTPase	system	provides	a	unique	system	to	
quickly	transduce	the	signal	to	the	integrin	and	thus	facilitate	platelet	
adhesion	 under	 shear	 stress	 conditions.	 Interestingly,	 recent	 stud-
ies	suggest	 that	platelet	GTPase	signaling	 is	much	 less	 important	 in	
situations	where	 vascular	 lesions	 are	 very	 small.	 At	 sites	 of	 inflam-
mation,	single	platelets	plug	holes	in	the	vascular	lining	(Figure	1B),63 
tiny	lesions	induced	by	transmigrating	inflammatory	cells.64 Without 
platelets	 (severe	 thrombocytopenia),	 these	 vessels	 become	 leaky	
for	RBCs,	causing	hemorrhage	 in	 the	affected	areas.62 We have re-
cently demonstrated that GPCRs are not critical for platelet function 
in	this	setting.40,65	Instead,	vascular	integrity	at	sites	of	inflammation	
depends	strongly	on	platelet	ITAM	signaling,	mediated	by	GPVI	and	
CLEC-	2.	This	 ISTH	meeting	provided	 important	new	information	on	
the	molecular	mechanisms	underlying	this	unique	form	of	hemosta-
sis.	In	our	ongoing	studies,	we	observed	that	mice	lacking	both	RAP1	
isoforms,	RAP1A	and	RAP1B,	do	not	bleed	at	sites	of	 inflammation,	
even	though	classical	hemostasis	is	strongly	impaired	in	these	mice.41 
Our	findings	of	significant	bleeding	at	sites	of	inflammation	in	the	skin	
(reverse	passive	Arthus	 reaction)	of	Talin1-	deficient	mice,	 however,	
do	suggest	that	platelet	integrin	signaling	is	critical	in	the	prevention	
of	 inflammatory	hemorrhage.	There	are	several	questions	 that	arise	
from	 these	 observations.	 For	 example,	why	 do	we	 observe	 inflam-
matory	bleeding	in	Talin1-	deficient	mice	while	no	such	bleeding	was	
observed	in	mice	lacking	αIIbβ362?	Like	GPCRs,	αIIbβ3 is particularly 
important	for	platelet-	platelet	aggregate	formation.	The	adhesion	to	
the	ECM,	however,	can	also	be	mediated	by	β1	integrins,	such	as	α2β1 
(collagen)	and	α6β1	(laminin).	Thus,	it	 is	likely	that	a	redundancy	be-
tween β3 and β1	integrins	in	mediating	platelet	adhesion	to	the	ECM	
protects β3-	deficient	mice	from	inflammatory	hemorrhage,	a	hypoth-
esis	that	warrants	further	 investigation.	Another	 important	question	
is why Rap1-	deficiency	does	not	cause	inflammatory	hemorrhage	like	
Talin1-	deficiency,	while	both	RAP1	and	TALIN1	are	critical	for	classi-
cal	hemostasis?	Our	preliminary	studies	presented	at	the	ISTH	confer-
ence	show	that	platelets	lacking	RAP1A	and	RAP1B	retain	a	weak	but	
significant	ability	 to	activate	 integrins	 in	 response	 to	agonist	 stimu-
lation.41	The	 resulting	 slow	aggregation	 response	observed	 in	 vitro,	
however,	 is	 not	 sufficient	 for	 hemostatic	 plug	 formation	 at	 sites	 of	
mechanical injury.41	How	RAP1-	deficient	platelets	manage	to	prevent	
inflammatory	hemorrhage	is	currently	not	clear.	A	likely	explanation	
is that shear stress is less of a factor in this situation as platelets may 
simply	 get	 trapped	 in	 the	 ECM	 (Figure	1B).	 If	 that	 is	 the	 case	 then	
the	delay	 in	 integrin	activation	 in	Rap1-	deficient	platelets	would	be	
negated	by	this	trapping	mechanism,	which	retains	platelets	in	the	EC	
gaps	long	enough	for	integrins	to	get	engaged.
Our	preliminary	studies	also	demonstrate	that	inflammatory	hemor-
rhage	is	significantly	less	severe	in	Talin1-	deficient	mice	when	compared	
to thrombocytopenic mice.41	This,	of	course,	begs	the	question	about	the	
nature	of	this	TALIN	(maybe	integrin)-	independent	contribution	of	plate-
lets	to	vascular	integrity	in	inflammation.	One	potential	explanation	that	
was	brought	forward	at	the	ISTH	meeting	is	that	CLEC2,	the	hemITAM	
signaling	receptor	critical	in	this	response,	may	serve	as	an	adhesion	re-
ceptor	in	addition	to	its	function	in	platelet	activation.	As	outlined	in	the	
abstract	by	Haining	et	al.,	studies	in	mice	expressing	a	signaling	defective	
mutant	of	CLEC2	(Y7A	KI)	suggest	a	signaling-	independent	contribution	
of	the	CLEC2	ectodomain	to	thrombus	stability38,39	A	similar	signaling-	
independent,	adhesive	role	was	also	reported	for	GPVI.36,37
Another	 interesting	 study	 on	 this	 topic	 was	 presented	 at	 ISTH	
2017	by	Rayes	et	al.,	who	demonstrated	that	podoplanin,	the	 ligand	
for	CLEC2,	is	found	in	the	deeper	layers	of	the	vasculature.66 The au-
thors	suggest	that	the	CLEC2-	podoplanin	interaction	is	required	as	a	
fail-	safe	in	case	GPVI	is	malfunctional,	a	hypothesis	that	is	supported	
by	 the	 observation	 that	megakaryocyte/platelet-	specific	 deletion	 of	
CLEC2	 in	mice	does	not	cause	 increased	 inflammatory	hemorrhage,	
unless	the	mice	are	crossed	with	GPVI-	deficient	mice.66	Interestingly,	
the	preliminary	studies	by	Rayes	et	al.	also	suggest	that	platelets	con-
tribute	to	vascular	integrity	in	LPS	challenged	lungs	by	a	GPVI/CLEC2-	
independent	 but	 GPIbα-	dependent	mechanism,	 findings	 that	 are	 in	
conflict	with	 previous	 findings.40	Additional	 studies	 are	 required	 to	
clarify	whether	there	is	indeed	an	organ	and/or	inflammatory	trigger-	
specific platelet response in this form of hemostasis.
Release	of	vasoactive	substances	from	platelet	granules	has	been	
proposed	as	another,	TALIN-	independent,	contribution	of	platelets	to	
vascular	 integrity	 in	 inflammation.67,68	 However,	 elegant	 studies	 by	
Deppermann	et	al.,	presented	at	the	2017	ISTH	meeting	and	recently	
published,69	question	this	hypothesis.	Utilizing	mice	with	a	defect	 in	
both	 alpha	 and	 dense	 granule	 secretion	 (Unc13d−/−/Nbeal2−/−),	 the	
authors	 investigated	 the	contribution	of	platelet	granule	content	on	
vascular	integrity	in	the	two	most	commonly	used	models	of	localized	
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inflammation:	 the	 reverse	 passive	 Arthus	 reaction	 in	 the	 skin,	 and	
LPS-	induced	 inflammation	 in	 the	 lung.	No	 increase	 in	 bleeding	was	
observed in inflamed tissues of Unc13d−/−/Nbeal2−/− mice when 
compared	to	controls.	This	result	does	not	exclude	a	contribution	of	
platelet	granule	secretion	to	vascular	integrity	in	inflammation,	but	it	
does	suggest	that	such	a	contribution	would	not	be	required	during	
the	acute	phase	of	the	hemostatic	response.	Interestingly,	the	authors	
did	 observe	 significant	 bleeding	 in	 Unc13d−/−/Nbeal2−/− mice chal-
lenged	in	a	model	of	thrombo-	inflammation	in	the	brain.	This	finding	
is	interesting	as	previous	studies	demonstrated	that	hemostasis	in	this	
model	is	dependent	on	integrin	αIIbβ3,	but	not	GPVI	and	GPIb-	V-	IX.70 
These	results	could	be	explained	by	(i)	brain	ischemia-	reperfusion	in-
jury	inducing	an	inflammatory	injury	to	the	vasculature	that	requires	a	
unique	platelet	response,	or	(ii)	intermediate	size	lesions	being	gener-
ated	following	brain	ischemia-	reperfusion	injury,	which	require	plate-
lets	to	release	their	granules	and	to	aggregate.
3  | CONCLUSIONS
Decades of research have uncovered many of the molecular mecha-
nisms	 underlying	 platelet	 activation	 and	 adhesion	 at	 sites	 of	 vascular	
injury.	 In	 this	 review,	we	provide	an	overview	of	 the	main	 regulatory	
mechanisms	controlling	platelet	reactivity,	both	in	circulation	and	at	the	
vascular	interface.	We	also	discuss	the	latest	developments	in	this	field,	
presented	at	this	year’s	ISTH	meeting.	These	studies	provide	critical	new	
information	on	the	platelet	signaling	machinery,	filling	gaps	but	also	chal-
lenging	our	current	thinking	of	how	platelets	work.	We	are	excited	to	see	
whether	the	many	important	scientific	questions	raised	by	these	studies	
can	be	answered	in	time	for	presentation	at	the	next	ISTH	meeting.
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